Myriad Genetics Inc (MYGN.O)

MYGN.O on Nasdaq

37.31USD
3:45pm EDT
Price Change (% chg)

$-0.20 (-0.53%)
Prev Close
$37.51
Open
$37.25
Day's High
$37.80
Day's Low
$37.00
Volume
308,753
Avg. Vol
938,283
52-wk High
$42.50
52-wk Low
$20.02

MYGN.O

Chart for MYGN.O

About

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the... (more)

Overall

Beta: 0.99
Market Cap (Mil.): $2,730.54
Shares Outstanding (Mil.): 72.80
Dividend: --
Yield (%): --

Financials

  MYGN.O Industry Sector
P/E (TTM): 16.44 39.72 34.30
EPS (TTM): 2.28 -- --
ROI: 23.77 7.11 18.12
ROE: 24.35 11.46 18.84
Search Stocks

Myriad's Huttenlocher bets on a weaker Chinese yuan

HONG KONG, June 12 - Betting on a weaker Chinese currency is the best way for investors to protect an equity portfolio as China enters a protracted period of slowing growth, said Carl Huttenlocher, chief investment officer of Myriad Asset Management.

12 Jun 2014

US STOCKS-Wall Street little changed, near record highs

NEW YORK, March 11 - U.S. stocks were little changed on Tuesday as investors found few reasons to push the S&P 500 above its recent record high, as tensions in Ukraine continued.

11 Mar 2014

US STOCKS-Wall Street to open flat as Ukraine tensions eyed

NEW YORK, March 11 - U.S. stocks were set for a flat open on Tuesday after a slight decline in the prior session left the S&P 500 within striking distance of its recent record high and amid investor caution as tensions in Ukraine continued.

11 Mar 2014

Court denies Myriad motion to block rival genetic tests

- Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company.

11 Mar 2014

UPDATE 1-US court denies Myriad motion to block rival genetic tests

March 11 - Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company.

11 Mar 2014

US STOCKS-Futures little changed as Ukraine eyed

* Futures: Dow off 8 pts, S&P off 1.25 pt, Nasdaq up 0.25 pt

11 Mar 2014

US court denies Myriad Genetics' motion to block rival

March 11 - Diagnostics company Myriad Genetics Inc said a U.S. court denied a motion that would have stopped rival Ambry Genetics Corp from selling a similar version of Myriad's cancer test.

11 Mar 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks